Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans Flora Moujaes, Katrin H. Preller, Jie Lisa Ji, John D. Murray, Lucie Berkovitch, Franz X. Vollenweider, Alan Anticevic Biological Psychiatry, 2023 doi : 10.1016/j.biopsych.2022.10.021 ABSTRACT Precision psychiatry aims to identify markers of inter-individual variability that allow predicting the right treatment for each patient. However, bridging the gap between molecular-level manipulations and neural systems-level functional alterations remains an unsolved problem in psychiatry. After decades of low success rates in pharmaceutical R&D for psychiatric drugs, multiple studies now point to the potential of psychedelics as a promising fast-acting and long-lasting treatment for some psychiatric symptoms. Yet, given the highly [...]
Lire la suiteThe Efficacy of MDMA (3,4- Methylenedioxymethamphetamine) for Post- traumatic Stress Disorder in Humans : A Systematic Review and Meta-Analysis Sarah Tedesco , Ganeya Gajaram , Shahzad Chida , Arham Ahmad , Meghan Pentak , Marina Kelada , Layth Lewis , Deepa Krishnan , Carolyn Tran , Oladipo T. Soetan , Lawrance T. Mukona , Ayodeji Jolayemi Cureus, 13, (5), e15070. Doi : 10.7759/cureus.15070 Abstract Background : 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as “Molly” or “Ecstasy”, is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological [...]
Lire la suiteEditorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder Daniel Feingold, Eva Hoch, Aviv Weinstein and Wayne Hall Frontiers in Psychiatry, 2021, Volume 12 | Article 789197 doi : 10.3389/fpsyt.2021.789197 Editorial on the Research Topic : Psychological Aspects of Cannabis Use and Cannabis Use Disorder Keywords : cannabis, marijuana, cannabis use disorder, psychology, cognition, emotion An increasing global prevalence of cannabis use has produced increased treatment seeking for Cannabis Use Disorder (CUD) and an increased research effort to identify factors associated with initiation of cannabis use, transitions to regular cannabis use and the onset of CUD (1, 2). The majority of empirical studies focus on biological and [...]
Lire la suiteCannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]
Lire la suiteCannabinoids and Endocannabinoids, and Prospective Modulation of EC Signaling in Neurodegenerative, Cardiovascular and Allied Disorders Dr Vinod Nikhra Preprint, May 2019 Doi : 10.13140/RG.2.2.36649.24165 ABSTRACT CANNABIS USE AND AVAILABILITY: The Cannabis derivatives have been used for recreational and medicinal purposes since ancient times. Because of the additive potential of cannabis products, their sale, possession and use are variously regulated in different countries throughout the world. Still as a psychoactive drug, cannabis continues to find extensive favour among recreational and medical users in the USA and other countries having led to decriminalise cannabis use for recreational and medicinal purposes. ECS: RECEPTORS, LIGANDS AND SIGNALING: The endocannabinoid system comprises [...]
Lire la suiteMECHOULAM ON THE FUTURE OF CANNABINOID RESEARCH The father of cannabis science emphasized three key areas to pursue By Martin A. Lee on March 15, 2023 I was fortunate to cross paths with Raphael Mechoulam, “the father of cannabis research,” at several science conferences over the years. The most memorable occasion was the 22nd annual meeting of the International Cannabinoid Research Society (ICRS) in Freiburg, Germany, in July 2012. Mechoulam delivered a plenary speech at the symposium, addressing the future of cannabinoid research and key areas of study that should be pursued. It was exactly fifty years earlier, in 1962, when Mechoulam launched his [...]
Lire la suiteAre cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review John M McPartland, Marnie Duncan, Vincenzo Di Marzo and Roger G Pertwee British Journal of Pharmacology, 2015, 172, 737-753. Doi : 10.1111/bph.12944 Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ9-tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 [...]
Lire la suiteBIBLIOGRAPHIE : Cannabinoïdes et maladies neurodégénératives Dr Christian Sueur, GRECC, mars 2022.
Lire la suiteCirculating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1 The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]
Lire la suiteLong-Term Efficacy for Epidiolex in Resistant Epilepsy Pauline Anderson Medscape - Dec 17, 2018. https://www.medscape.com/viewarticle/906653 NEW ORLEANS — Results of open-label extension trials show the recently approved drug Epidiolex (GW Pharmaceuticals), a purified formulation of cannabidiol (CBD), is safe and effective beyond a year in patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome, two rare and resistant epilepsy types. "We now have long-term data to say that it still works; the efficacy is not going to drop off, and more importantly, it's still going to be safe and you're not going to learn anything new down the road," study author Anup D. Patel, MD, Section Chief of Pediatric Neurology, [...]
Lire la suite